Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

DILANTIN SODIUM THERAPY IN EPILEPSY

DILANTIN SODIUM THERAPY IN EPILEPSY Dilantin sodium was introduced by Merritt and Putnam1 as a treatment for convulsant disorders, after experimental studies had shown its efficacy as an anticonvulsant.2 In their first clinical contribution they reported favorable results in 200 cases, in the majority of which there were frequent convulsive seizures. They conclude their article with the statement "Sodium diphenyl hydantoinate is a valuable addition to the physician's armamentarium in the battle against epilepsy. Its use should be restricted for the present to that group of patients who do not respond to the less toxic forms of therapy previously in common use." Through the courtesy of Dr. J. D. Ralston, of Parke, Davis & Co., a liberal supply of this medicament was made available for a clinical trial. In May 1938 treatment was started on several private patients and then extended to the members of an outpatient epileptic clinic at Lakeside Hospital. Patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

DILANTIN SODIUM THERAPY IN EPILEPSY

JAMA , Volume 114 (5) – Feb 3, 1940

Loading next page...
 
/lp/american-medical-association/dilantin-sodium-therapy-in-epilepsy-0NyU7uVNZ4

References (6)

Publisher
American Medical Association
Copyright
Copyright © 1940 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1940.02810050016004
Publisher site
See Article on Publisher Site

Abstract

Dilantin sodium was introduced by Merritt and Putnam1 as a treatment for convulsant disorders, after experimental studies had shown its efficacy as an anticonvulsant.2 In their first clinical contribution they reported favorable results in 200 cases, in the majority of which there were frequent convulsive seizures. They conclude their article with the statement "Sodium diphenyl hydantoinate is a valuable addition to the physician's armamentarium in the battle against epilepsy. Its use should be restricted for the present to that group of patients who do not respond to the less toxic forms of therapy previously in common use." Through the courtesy of Dr. J. D. Ralston, of Parke, Davis & Co., a liberal supply of this medicament was made available for a clinical trial. In May 1938 treatment was started on several private patients and then extended to the members of an outpatient epileptic clinic at Lakeside Hospital. Patients

Journal

JAMAAmerican Medical Association

Published: Feb 3, 1940

There are no references for this article.